DNA Chip Based Prognosis of Lung Cancer
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | June 2008 |
| End Date: | September 2014 |
The purpose of the study is to determine whether a DNA chip, designed by Medical Prognosis
Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous
and large cell lung cancer).
Institute (MPI), can provide an accurate prognosis for survival of NSCLC (adeno-, squamous
and large cell lung cancer).
Inclusion Criteria:
1. A histological diagnosis of primary NSCLC stage Ia
2. Surgical removal of the tumor
3. Age between 18 and 75 years
4. Ability to understand and the willingness to sign a written informed consent
document.
Exclusion Criteria:
1. A primary NSCLC stage Ia diagnosis that is changed to not primary NSCLC or NSCLC
stage Ib-IV after surgery.
2. Adjuvant treatment with chemotherapy.
3. Prior history of cancer in the past 5 years or breast cancer at any time.
4. Life expectancy less than 3 years in the opinion of the investigator due to
concurrent illnesses.
We found this trial at
3
sites
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
Click here to add this to my saved trials